Clinical Trial Update: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating the combination of vemurafenib and obinutuzumab in patients with previously untreated classical hairy cell leukemia; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hairy Cell Leukemia, Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING